|Bid||20.88 x 2200|
|Ask||20.89 x 1300|
|Day's Range||20.67 - 21.46|
|52 Week Range||17.11 - 37.75|
|Beta (5Y Monthly)||1.78|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 12, 2020 - Feb 17, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.73|
The EC grants marketing authorization to Amgen (AMGN) and partner UCB's Evenity for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture.
Shares of Alkermes were down 2.74% after the Food and Drug Administration published a warning letter alleging Vivitrol ads didn't include important risk information. If Vivitrol, which is used to prevent relapses in opioid addiction and is the drugmaker's top-selling drug, is used in conjunction with a previously tolerated dose of opioids, it can lead to an overdose. That information was not included in a print ad marketing the drug to the criminal justice system. The FDA told Alkermes to stop publishing the ad and to submit a response to the regulatory agency by Dec. 16. "The criminal justice system is an important aspect for us as people are more and more focused obviously on drug offenses and as opposed to violent offenses, how people can get treatment behind the walls. The prison system in the United States is not set up to deliver treatment," CFO James Frates told investors in July, according to a FactSet transcript of a Q2 earnings call. Vivitrol brought in $85.1 million in sales in the third quarter of 2019, up from $79.9 million in the same period in 2018. Alkermes' stock has dropped 29% year-to-date. The S&P 500 is up about 25%.
A print advertisement of Alkermes Plc's addiction treatment, Vivitrol, is false or misleading as it omits important risk information associated with its use, the Food and Drug Administration said in a warning letter http://bit.ly/2LGVKUM to the company. Users of Vivitrol as a treatment for opioid dependence should be made aware of the vulnerability to potentially fatal overdose at the end of a dosing interval, after missing a dose, or after discontinuing the treatment, the agency said in the letter dated Dec. 2. Vivitrol, used to prevent a relapse to opioid dependence following detoxification and to treat alcohol dependence, is one of Alkermes' top-selling drugs and brought in $85.2 million in the latest reported quarter.
TG Therapeutics (TGTX) announces positive first clinical data from its once daily, oral, BTK inhibitor, TG-1701, as a single agent and as a triple therapy in combination.
Regeneron (REGN) reports initial data for REGN5458, a BCMAxCD3 bispecific antibody, in patients with relapsed or refractory (R/R) multiple myeloma.
bluebird (BLUE) and partner Bristol-Myers report positive top-line results from a phase II study on idecabtagene vicleucel in patients with relapsed and refractory multiple myeloma.
Richard Pops has been the CEO of Alkermes plc (NASDAQ:ALKS) since 2011. This analysis aims first to contrast CEO...
Sage Therapeutics' (SAGE) phase III study on pipeline candidate SAGE-217 for the treatment of major depressive disorder fails to meet the primary endpoint.
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
Ra Pharmaceuticals (RARX) begins dosing of the first patient in its phase II study of zilucoplan for the treatment of immune-mediated necrotizing myopathy.
Zealand (ZEAL) announces initiation of the second phase III study to evaluate dasiglucagon in pediatric patients with congenital hyperinsulinism.
AstraZeneca (AZN) divests commercial rights to its schizophrenia and bipolar disorder medicines Seroquel/Seroquel XR in the United States and Canada to Cheplapharm Arzneimittel GmbH.
The EMA validates Amarin's (AMRN) regulatory application seeking approval for Vascepa as a treatment to reduce risk of cardiovascular events.
BioDelivery's (BDSI) efforts to increase preferred coverage for Belbuca and the acquisition of the rights to Symproic are likely to help continue its momentum.
ChemoCentryx (CCXI) announces positive data pivotal study evaluating its lead candidate, avacopan, in patients with ANCA vasculitis, a rare disease affecting small blood vessels.
Alkermes plc (Nasdaq: ALKS) today announced that it has completed its previously announced acquisition of Rodin Therapeutics, Inc. (Rodin), a privately held biopharmaceutical company. This transaction builds on Alkermes' experience in central nervous system (CNS) diseases and expands Alkermes' CNS development efforts into a wide range of neurodegenerative disorders.